⌘K
Loading ticker…
Ligand Pharmaceuticals Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ligand Pharmaceuticals Inc. (LGND) has a 3-month relative strength percentile of 89 and a leadership percentile of 98 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 74. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.2%, relative volume 3.06×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 89, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
LGND is in a stage 2 uptrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 27.8% / 48.5%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
LGND is held by 9 ETFs as of Mar 2026. Top owner: IJR at 0.26% weight, $236M notional. Top 3 carry $449M.
Top 9 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJRiShares Core S&P Small-Cap ETF | 0.26% | $236M |
| VTIVanguard Total Stock Market ETF | 0.01% | $119M |
| IWMiShares Russell 2000 ETF | 0.13% | $95M |
| VBVanguard Small Cap ETF | 0.05% | $86M |
| VBRVanguard Small Cap Value ETF | 0.09% | $55M |
| VXFVanguard Extended Market ETF | 0.05% | $44M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $5M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.73% | $5M |
| IWOiShares Russell 2000 Growth ETF | 0.03% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LGND Jan avg: 4.27% median: 3.35% win: 100% σ: 3.22% n: 4 2022-04-12 → 2026-05-29 | LGND Feb avg: 5.04% median: 4.19% win: 100% σ: 2.45% n: 4 2022-04-12 → 2026-05-29 | LGND Mar avg: -4.80% median: -3.60% win: 50% σ: 7.52% n: 4 2022-04-12 → 2026-05-29 | LGND Apr avg: 1.30% median: 3.79% win: 60% σ: 10.24% n: 5 2022-04-12 → 2026-05-29 | LGND May avg: 0.67% median: -4.25% win: 40% σ: 12.29% n: 5 2022-04-12 → 2026-05-29 | LGND Jun avg: 3.39% median: 1.62% win: 75% σ: 5.47% n: 4 2022-04-12 → 2026-05-29 (current) | LGND Jul avg: 10.27% median: 9.45% win: 75% σ: 15.80% n: 4 2022-04-12 → 2026-05-29 | LGND Aug avg: 4.66% median: -0.67% win: 50% σ: 12.24% n: 4 2022-04-12 → 2026-05-29 | LGND Sep avg: -2.89% median: -6.10% win: 25% σ: 8.41% n: 4 2022-04-12 → 2026-05-29 | LGND Oct avg: 0.66% median: 3.70% win: 75% σ: 9.29% n: 4 2022-04-12 → 2026-05-29 | LGND Nov avg: 3.95% median: 8.86% win: 75% σ: 14.31% n: 4 2022-04-12 → 2026-05-29 | LGND Dec avg: -1.15% median: -7.66% win: 25% σ: 15.89% n: 4 2022-04-12 → 2026-05-29 |